Your browser doesn't support javascript.
loading
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.
Guida, M; Strippoli, S; Maule, M; Quaglino, P; Ramondetta, A; Chiaron Sileni, V; Antonini Cappellini, G; Queirolo, P; Ridolfi, L; Del Vecchio, M; Cocorocchio, E; Di Giacomo, A M; Festino, L; Merelli, B; Occelli, M; Brugnara, S; Minisini, A; Sava, S; Tommasi, S; De Summa, S.
Afiliación
  • Guida M; Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy. Electronic address: micguida57@gmal.com.
  • Strippoli S; Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Maule M; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Quaglino P; Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy.
  • Ramondetta A; Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy.
  • Chiaron Sileni V; Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Antonini Cappellini G; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy.
  • Queirolo P; Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Ridolfi L; Medical Oncology Department, IRCCS National Cancer Research Centre, Meldola (FO), Italy.
  • Del Vecchio M; Medical Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS, Milan, Italy.
  • Cocorocchio E; Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Di Giacomo AM; Center for Immuno-Oncology University Hospital of Siena, Siena, Italy.
  • Festino L; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale, Naples, Italy.
  • Merelli B; Department of Medical Oncology, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Occelli M; Department of Medicine, Clinical Oncology and Translational Research, Azienda Ospedaliera Santa Croce and Carle University Teaching Hospital, Cuneo, Italy.
  • Brugnara S; Oncology Unit, S. Chiara Hospital, Trento, Italy.
  • Minisini A; Department of Oncology, ASUIUD University Hospital of Udine, Udine, Italy.
  • Sava S; Medical Oncology Unit, A.O. Papardo & Department of Human Pathology, University of Messina, Messina, Italy.
  • Tommasi S; Molecular Diagnostic and Pharmacogenetics Laboratory, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • De Summa S; Molecular Diagnostic and Pharmacogenetics Laboratory, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
ESMO Open ; 6(2): 100064, 2021 04.
Article en En | MEDLINE | ID: mdl-33711672
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vitíligo / Ipilimumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vitíligo / Ipilimumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2021 Tipo del documento: Article